MTE #39: Fontan-Associated Liver Disease: When to Consider Combined Heart and Liver Transplant

Nov 10 2025
Convention Center: Room 149, Level 1
12:45 PM - 1:30 PM
Ticketed Event

World Class Speakers

AS
Discussion Leader

Alexandra Shingina

University of Michigan
Daniel Ganger, MD, FAASLD
Discussion Leader

Daniel Ganger, MD, FAASLD

Northwestern Memorial Hospital

Description

Experts review the pathophysiology of Fontan-associated liver disease and the associated risk of developing hepatocellular carcinoma. Presenters also discuss the management of Fontan-associated liver disease, indications for combined heart and liver transplantation, and posttransplant outcomes.

Journey Maps

Objectives

  • Explain the pathophysiology of Fontan-associated liver disease.
  • Review the management of Fontan-associated liver disease, including surveillance for hepatocellular carcinoma.
  • Identify the indications for a combined heart and liver transplant in the setting of Fontan-associated liver disease.